Transplant Rejection: Mechanisms and Treatment

Archives of Surgery

Volumn 128, Issue 3, 1993, Pages 279-283

  Chandler, Charles ^a   Passaro, Edward ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ANTIGEN BINDING; ANTIGEN FUNCTION; BLOOD TOXICITY; CELLULAR IMMUNITY; CORTICOSTEROID THERAPY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0027479002     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.1993.01420150033006     Document Type: Article

References (54)

1. Little CC, Tyzzer EE. Further experimental studies on the inheritance of susceptibility to a transplantable tumor carcinoma (J.W.A.) of the Japanese waltzing mouse. J Med Res. 1916;33:393-427.
2. Robinson MA, Kindt TJ. Major histocompatibility complex antigens and genes. In: Paul WE, ed. Fundamental Immunology. 2nd ed. New York, NY: Raven Press; 1989:489-539.
3. Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ. Sequential analysis of HLA-class II antigen expression in human renal allografts. Transplantation. 1986;42:144-150.
4. Zinkernagel RM, Doherty PC. Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogenic system. Nature. 1974;248:701-702.
5. Davis MM, Bjorkman PJ. T-cell receptor genes and T-cell recognition. Nature. 1988;334:395-402.
6. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med. 1990;322:510-517.
7. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol. 1989;44:265-311.
8. Larsen CP, Austyn JM, Phil D, Morris PJ. The role of graft-derived dendritic leukocytes in the rejection of vascularized organ allografts. Ann Surg. 1990;212:308-317.
9. Halloran PF, Cockfield SM, Madrenas J. The mediators of inflammation (interleukin 1, interferon-gamma, and tumor necrosis factor) and their relevance to rejection. Transplant Proc. 1989;21:26-30.
10. Cantrell PA, Smith KA. The interleukin 2 T cell system: a new cell growth model. Science. 1984;224:1312-1316.
11. Howard M, Matis L, Malek TR, et al. Interleukin 2 induces antigen-reactive T cell line to secrete BCGF-1. J Exp Med. 1983;158:2024-2039.
12. Inaba K, Granelli-Piperno A, Steinman RM. Dendritic cells induce T lymphocytes to release B-cell-stimulating factors by an interleukin 2-dependent mechanism. J Exp Med. 1983;158:2040-2057.
13. Smith KA. The two-chain structure of high-affinity IL-2 receptors. Immunol Today. 1987;8:11-13.
14. Matsushima K, Openheim JJ. Interleukin-8 and MCAF: novel inflammatory cytokines induced by IL-1 and TNF. Cytokine. 1989;1:2-13.
15. Tracey KJ, Lowry SF, Cerami A. Physiological responses to cachectin. In: Bock G, Marsh J, eds. Tumor Necrosis Factor and Related Cytotoxins. New York, NY: John Wiley & Sons Inc; 1987:88-108.
16. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988; 318:1481-1486.
17. Schirmer WJ, Shirmer JM, Fry DE. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg. 1989;124:445-448.
18. Ihle JN, Weinstein Y. Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin-3. Adv Immunol. 1986;39: 1-50.
19. Shinkai Y, Takio K, Okumura K. Homology of perform to the ninth component of complement (C9). Nature. 1988;334:525-527.
20. Morris PJ. Rejection: unanswered questions. Hum Immunol. 1990; 28:104-111.
21. Murray JE, Merrill JP, Dammin GJ, et al. Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery. 1960;48:272-284.
22. Calne RY, Alexandre GPJ, Murray JE. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann N Y Acad Sci. 1962;99:743-761.
23. Murray JE. Remembrances of the early days of transplantation. Transplant Proc. 1981;13(suppl):3-5.
24. Borel JF. Cyclosporine: historical perspectives. Transpl Proc. 1983;15 (suppl):2219-2229.
25. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science. 1989;246:1617-1620.
26. Thompson AW. FK-506: how much potential? Immunol Today. 1989; 10:6-9.
27. Beck Y, Akiyama N. Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. Transplant Proc. 1989;21:3464-3467.
28. Todo S, Fung J, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK-506. Ann Surg. 1990;212:295-307.
29. Morris RE, Wu J, Shorthouse R. A study contrasting effects of cyclosporine, FK-506, and rapamycin on suppression of allograft rejection. Transplant Proc. 1990;22:1638-1641.
30. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet. 1967; 124:301-318.
31. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
32. Rinnooy Kan EA, Wright SD, Welte K, Wang CY. Fc receptors on monocytes cause OKT3 treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol. 1986;98:181-187.
33. Shield CF, Norman DJ. Immunologic monitoring during and after OKT3 therapy. Am J Kidney Dis. 1988;11:120-124.
34. Colonna JO, Goldstein LI, Brems JJ, et al. A prospective study on the use of monoclonal anti-T3 cell antibody (OKT3) to treat steroid resistant liver transplant rejection. Arch Surg. 1987;122:1120-1123.
35. Millis JM, McDiarmid SV, Hiatt JR, et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation. 1989;47:82-88.
36. Norman DJ, Shield CF, Henell KR, et al. Effectiveness of a second course of OKT3 for treatment of renal allograft rejection. Transplantation. 1988;46:523-529.
37. Goldstein G, Fuccello AG, Norman DJ, Shield CF, Colvin RB, Cosimi AB. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 1986;42: 507-510.
38. Norman DJ. The clinical role of OKT3. Immun Allergy Clin North Am. 1989;9:95-105.
39. Tellides G, Dallman MJ, Morris PJ. Synergistic interaction of cyclosporin A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc. 1988;20:202-206.
40. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990;322:1175-1182.
41. Imagawa DK, Millis JM, Olthoff KM, et al. Anti-tumor necrosis factor antibody enhances allograft survival in rats. J Surg Res. 1990;48:345-348.
42. Didlake RH, Kim E, Sheehan K, Schrieiber RD, Kahan BD. Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat. Transplantation. 1988;45:222-223.
43. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complimentarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522-525.
44. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;322:323-327.
45. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, Fitzgerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas endotoxin. Nature. 1989;339:394-397.
46. Strom TB, Kelley VE. Toward more selective therapies to block undesired immune responses. Kidney Int. 1989;35:1026-1033.
47. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science. 1990;248: 739-741.
48. Cicciarelli J, Terasaki PI, Mickey MR. The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients. Transplantation. 1987;43:636-640.
49. Morris PJ. Histocompatibility antigens and transplantation reflections over 20 years. Immunol Lett. 1989;21:25-32.
50. Faustman DL, Steinman RM, Gebel HM, Hauptfeld V, Darie JM, Lacy PE. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci U S A. 1984;81:3864-3868.
51. Iwai H, Kuma S-I, Inaba M, et al. Acceptance of murine thyroid allografts by pretreatment of anti-la antibody or anti-dendritic cell antibody in vitro. Transplantation. 1989;47:45-49.
52. Taube D, Welsh K, Bewick M, et al. Pretreatment of human renal allografts with monoclonal antibodies to endure long-term tolerance. Transplant Proc. 1987;19:1961-1963.
53. Brewer T, Taube D, Bewick M, et al. Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection. Lancet. 1989;2:935-937.
54. Madsen JC, Superina RA, Wood KJ, Morris PJ. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature. 1988;332:161-164.